| Autor: |
García M; Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.; Hospital Universitario Rey Juan Carlos, Móstoles, Spain., Navarrete-Muñoz MA; Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.; Hospital Universitario Rey Juan Carlos, Móstoles, Spain., Ligos JM; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain., Cabello A; Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Restrepo C; Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.; Hospital Universitario Rey Juan Carlos, Móstoles, Spain., López-Bernaldo JC; Hospital General Universitario Gregorio Marañón, Madrid, Spain., de la Hera FJ; Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Barros C; Hospital Universitario de Móstoles, Móstoles, Spain., Montoya M; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain., Fernández-Guerrero M; Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Estrada V; Hospital Universitario Clínico San Carlos, Madrid, Spain., Górgolas M; Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Benito JM; Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain. jbenito1@hotmail.com.; Hospital Universitario Rey Juan Carlos, Móstoles, Spain. jbenito1@hotmail.com., Rallón N; Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain. normaibon@yahoo.com.; Hospital Universitario Rey Juan Carlos, Móstoles, Spain. normaibon@yahoo.com. |
| Abstrakt: |
A recent study has pointed out to CD32a as a potential biomarker of HIV-persistent CD4 cells. We have characterized the level and phenotype of CD32+ cells contained in different subsets of CD4 T-cells and its potential correlation with level of total HIV-DNA in thirty HIV patients (10 typical progressors naïve for cART, 10 cART-suppressed patients, and 10 elite controllers). Total HIV-DNA was quantified in different subsets of CD4 T-cells: Trm and pTfh cells. Level and immunephenotype of CD32+ cells were analyzed in these same subsets by flow cytometry. CD32 expression in Trm and pTfh subsets was similar in the different groups, and there was no significant correlation between the level of total HIV-DNA and the level of CD32 expression in these subsets. However, total HIV-DNA level was correlated with expression of CD127 (rho = -0.46, p = 0.043) and of CCR6 (rho = -0.418, p = 0.027) on CD32+ cells. Our results do not support CD32 as a biomarker of total HIV-DNA content. However, analyzing the expression of certain markers by CD32+ cells could improve the utility of this marker in the clinical setting, prompting the necessity of further studies to both validate our results and to explore the potential utility of certain markers expressed by CD32+ cells. |
